Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Paediatrics

Dasotraline shows potential for improving ADHD symptom severity

Research published in the Journal of Child and Adolescent Psychopharmacology has suggested that once-daily dasotraline is a promising therapeutic option for the treatment of attention deficit hyperactivity disorder.

Child with ADHD daydreaming

Source: Shutterstock.com

Dasotraline, an inhibitor of presynaptic dopamine and norepinephrine reuptake and, unlike amphetamines, has shown potential in the treatment of attention deficit hyperactivity disorder in children aged 6–12 years

A novel treatment has been found to be effective in improving symptoms of attention deficit hyperactivity disorder (ADHD) in children, such as attention and hyperactivity[1].

Researchers randomly assigned 342 children aged 6–12 years with ADHD to dasotraline (2mg or 4mg) or placebo once daily for six weeks.

ADHD symptom severity, as measured on an 18-item 4-point scale, decreased by 17.5 points on average in the dasotraline 4mg group compared with 11.4 points in the placebo group. The change in score in the dasotraline 2mg group (–11.8) was not significantly different to placebo.

The most common adverse events in the dasotraline group included insomnia, decreased appetite, decreased weight and irritability.

Dasotraline is an inhibitor of presynaptic dopamine and norepinephrine reuptake and, unlike amphetamines, which are also effective in ADHD, it does not stimulate dopamine production, which can lead to dependency and abuse.

“The results of the current study provide efficacy and safety data indicating that dasotraline, dosed once-per-day, is a promising therapeutic option for the treatment of ADHD, with a reduced potential for abuse,” the team concluded in the Journal of Child and Adolescent Psychopharmacology (7 March 2019).

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206375

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.